Rheumatic Myocarditis Treatment Market Size

Rheumatic Myocarditis Treatment Market size was valued at USD 1.05 Billion in 2023 and is anticipated to reach USD 1.95 Billion by the end of 2036, registering around 4.9% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of rheumatic myocarditis treatment is assessed at USD 1.1 Billion. The major factor attributed to market growth is the rising incidence of rheumatic heart disease among the global population and the increasing prevalence of rheumatic fever which is generating the need for rheumatic myocarditis treatment during the forecast period. According to a recently published report in 2021, it is estimated that around 34 million people around the world have rheumatic heart disease. Moreover, it is being calculated that 300,000 to 500,000 new cases of rheumatic fever are diagnosed every year worldwide.

In addition to the aforementioned factors, the rapid advancement in drugs and biotechnology is estimated to bring in lucrative growth opportunities for the expansion of the global rheumatic myocarditis treatment. Apart from this, the escalation in cases of rheumatic fever, and strep throat along with the growing prevalence of inflammatory diseases around the world is anticipated to create a positive outlook for market growth during the forecast period. Furthermore, another factor that is estimated to drive the rising focus of the governments of different nations to enhance healthcare facilities and medical offerings. Also, the rising cases of chronic diseases and cardiovascular disorders which lead to rheumatic myocarditis are forecasted to generate a high demand for rheumatic myocarditis treatment which is estimated to subsequently increase the market size in the upcoming years.